Computational investigations of flavonoids as ALDH isoform inhibitors for treatment of cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identified potent flavonoid inhibitors targeting human aldehyde dehydrogenases (ALDHs), enzymes crucial in cancer stem cells. These compounds show promise for developing novel cancer therapies by downregulating ALDH activity.
Area Of Science
- Biochemistry
- Pharmacology
- Computational Chemistry
Background
- Human aldehyde dehydrogenases (ALDHs) are overexpressed in cancer stem cells (CSCs), contributing to cancer progression and therapeutic resistance.
- Targeting ALDH isoforms presents a promising strategy for innovative cancer treatments.
- Flavonoids exhibit anticancer properties by modulating cancer-related pathways, including ALDH activity.
Purpose Of The Study
- To computationally screen 830 flavonoids against five key ALDH isoforms (ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, ALDH3A1).
- To identify specific and multi-target ALDH inhibitors with potential anticancer activity.
- To evaluate the drug-like properties of identified flavonoid inhibitors.
Main Methods
- Utilized Extra Precision (XP) Glide docking and MM-GBSA calculations to assess binding affinities.
- Employed molecular dynamics (MD) simulations to analyze the stability and specificity of flavonoid-ALDH interactions.
- Conducted ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) property evaluations.
Main Results
- Several flavonoids demonstrated high binding affinities to target ALDH isoforms.
- Specific flavonoids (1, 2, 18, 27, 42) were identified as potential inhibitors for individual ALDH isoforms.
- Flavonoid 10 emerged as a potential multi-ALDH inhibitor, showing affinity for ALDH1A2, ALDH1A3, and ALDH3A1.
- Promising hits exhibited acceptable preliminary drug-like profiles.
Conclusions
- Computational screening identified potent flavonoid inhibitors for specific and multiple ALDH isoforms.
- These flavonoids represent promising candidates for future development as anticancer agents targeting ALDH.
- Further optimization is required to enhance therapeutic efficacy and reduce potential toxicity for clinical application.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...